|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM14428488X |
| 003 |
DE-627 |
| 005 |
20250205062428.0 |
| 007 |
tu |
| 008 |
231223s2003 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0481.xml
|
| 035 |
|
|
|a (DE-627)NLM14428488X
|
| 035 |
|
|
|a (NLM)14719450
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Uei, Takatoshi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical study of endocrine therapy in stage B and C prostate cancer
|
| 264 |
|
1 |
|c 2003
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.02.2004
|
| 500 |
|
|
|a Date Revised 15.11.2006
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a To evaluate the usefulness of endocrine therapy for stage B and C prostate cancer, we carried out a retrospective study on overall survival rate, cause-specific survival, PSA recurrence-free rate, and their predictive factors in 118 patients with stage B prostate cancer, 61 with stage C prostate cancer who underwent endocrine therapy at our department between 1985 and 2001. The cause-specific survival rate and PSA recurrence-free rate of stage B patients who underwent endocrine therapy were well, and they will take a good clinical course. Thus, in this stage of prostate cancer, aged patients and patients with complications may be good candidates for endocrine therapy. The cause-specific survival rate and PSA recurrence-free rate in the stage C patients who underwent endocrine therapy were significantly low. In stage C patients, endocrine therapy should be combined early with other methods such as radiotherapy. In the stage B patients who underwent endocrine therapy, PSA and Gleason score appeared to be associated with the cause-specific survival rate and PSA recurrence-free rate
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antineoplastic Agents, Hormonal
|2 NLM
|
| 700 |
1 |
|
|a Okazaki, Hiroshi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nakamura, Toshiyuki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Katou, Nobuo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Suzuki, Kazuhiro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yamanaka, Hidetoshi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 49(2003), 11 vom: 20. Nov., Seite 639-43
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:49
|g year:2003
|g number:11
|g day:20
|g month:11
|g pages:639-43
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 49
|j 2003
|e 11
|b 20
|c 11
|h 639-43
|